



Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
(617) 252-7570

Fast Facts About Genzyme Corporation

Founded:	1981
2009 Revenues:	\$4.5 billion
CEO:	Henri A. Termeer President 1983, CEO 1985, Chairman 1988
2009 R&D Spending:	\$804 million
Employees Worldwide:	More than 12,000
Headquarters:	Cambridge, MA
Exchange and Symbol:	Nasdaq, GENZ
Areas of Focus:	Personalized Genetic Health, Renal Disease, Endocrinology, Biosurgery, Hematologic Oncology, Transplant, Immune Diseases

Top Products, based on FY 2009 Revenue:

Product Name	Disease/Condition	Revenue 2009
Cerezyme [®] (imiglucerase for injection)	Gaucher disease	\$793 million
Sevelamer (Renagel [®] and Renvela [®])	renal disease	\$707 million
Fabrazyme [®] (agalsidase beta)	Fabry disease	\$431 million
Synvisc [®] (hylan G-F 20)	osteoarthritis of the knee	\$329 million

Key Pipeline Products:

Product Name	Disease/Condition
alemtuzumab	multiple sclerosis
mipomersen	high-risk hypercholesterolemia
eliglustat tartrate	Gaucher disease

International Presence:

Genzyme has more than 85 locations in over 40 countries, including 17 manufacturing facilities; the company's products are available in nearly 100 countries.

Charitable Contributions, FY 2009:

Global product donations, \$74 million; U.S. cash contributions, \$14 million.